Hepatic arterial infusion chemotherapy

PROCEDURE20 trials

Sponsors

Kaneko Shuichi, Sun Yat-sen University, Shi Ming, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Nanfang Hospital, Southern Medical University

Conditions

Advanced Colorectal CarcinomaAntimetabolitesAntineoplastic AgentsBevacizumabBiliary Tract CancerCarcinomaCarcinoma, HepatocellularDigestive System Neoplasms

Phase 1

Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC

Wan-Guang ZhangHepatocellular Carcinoma

Start: 2022-09-01End: 2025-02-28Target: 30Updated: 2023-12-19

Phase 2

Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma

CompletedNCT02981498

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2015-06-30End: 2017-04-30Target: 35Updated: 2019-03-06

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

WithdrawnNCT03803254

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2019-01-03End: 2021-01-01Updated: 2019-05-06

HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2018-11-05End: 2019-12-01Target: 100Updated: 2019-01-23

Randomized phase II study exploring better regimen of hepatic arterial infusion chemotherapy (HAIC) for the patients with advanced hepatocellular carcinoma

Active, not recruitingJPRN-jRCTs041180176

Kaneko ShuichiLiver cancer Liver cancer, Hepatocellualr carcinoma

Start: 2016-05-25Target: 125Updated: 2025-07-18

HAIC Plus Lenvatinib and Toripalimab for Advanced HCC

CompletedNCT04044313

Shi MingHepatocellular Carcinoma

Start: 2019-08-01End: 2022-02-28Updated: 2023-06-12

HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2019-10-20End: 2023-12-20Target: 60Updated: 2023-08-15

HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

Sun Yat-sen UniversityBevacizumab, Hepatocellular Carcinoma, Liver Neoplasms +2

Start: 2021-01-01End: 2023-06-30Target: 30Updated: 2020-11-13

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAntimetabolites, Antineoplastic Agents, Carcinoma +6

Start: 2023-07-01End: 2024-08-31Target: 30Updated: 2023-06-22

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

CompletedNCT05003700

Nanfang Hospital, Southern Medical UniversityHepatocellular Carcinoma

Start: 2021-08-12End: 2024-07-04Updated: 2024-11-05

Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

Peking University Cancer Hospital & InstituteAdvanced Colorectal Carcinoma, Liver Metastasis Colon Cancer

Start: 2022-02-25End: 2024-10-31Target: 27Updated: 2022-06-06

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Not yet recruitingNCT06389500

Harbin Medical UniversityBiliary Tract Cancer

Start: 2024-05-01End: 2028-05-01Target: 30Updated: 2024-04-29

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

RecruitingNCT06420440

Chen XiaopingHCC

Start: 2024-06-01End: 2027-05-31Target: 160Updated: 2025-05-01

Phase 3

Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC

CompletedNCT02774187

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2016-05-31End: 2018-08-31Updated: 2019-12-05

HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC

CompletedNCT02856126

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2016-08-31End: 2024-07-31Updated: 2024-07-23

HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.

CompletedNCT02973685

Sun Yat-sen UniversityHepatoCellular Carcinoma

Start: 2016-10-01End: 2020-11-28Updated: 2023-06-12

HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2018-12-12End: 2021-12-01Target: 250Updated: 2019-01-03

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

RecruitingNCT06201065

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2023-12-26End: 2026-12-26Target: 200Updated: 2024-01-11

Unknown Phase

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

CompletedNCT04618367

Sun Yat-sen UniversityCarcinoma, Hepatocellular, Liver Neoplasms, Portal Vein Tumor Thrombus +1

Start: 2021-01-01End: 2022-12-30Updated: 2024-03-06

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

RecruitingNCT06333561

Sun Yat-sen UniversityHepatic Arterial Infusion Chemotherapy, Hepatocellular Carcinoma, Lenvatinib +1

Start: 2021-01-01End: 2025-12-30Target: 300Updated: 2025-02-06

Related Papers

Supplementary Figure S1 from HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/-L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study

2026-02-17

Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing immune checkpoint inhibitor and concurrent antiviral prophylaxis agents: A prospective observational study.

Journal of Clinical Oncology2025-05-281 citations

Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: An update on SHATA-001 study.

Journal of Clinical Oncology2025-05-28

Camrelizumab combined with Lenvatinib and RALOX-HAIC for unresectable hepatocellular carcinoma (Cal Era): a prospective, single-arm, phase II trial

Liver Cancer2025-05-262 citations

A Contrast‐Enhanced Ultrasound Cine‐Based Deep Learning Model for Predicting the Response of Advanced Hepatocellular Carcinoma to Hepatic Arterial Infusion Chemotherapy Combined With Systemic Therapies

Cancer Science2025-04-29

Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (SHATA-001).

Journal of Clinical Oncology2024-06-011 citations

Phase Ib/II trial of hepatic arterial infusion chemotherapy in combination with fruquintinib for refractory unresectable colorectal cancer liver metastases.

Journal of Clinical Oncology2024-06-01

Postoperative adjuvant hepatic arterial infusion chemotherapy combined with donafenib in hepatocellular carcinoma with solitary large tumor and microvascular invasion: A multicenter, prospective, single-arm, phase II trial.

Journal of Clinical Oncology2024-06-01

Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study).

Journal of Clinical Oncology2023-06-017 citations

A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study).

Journal of Clinical Oncology2021-05-2031 citations

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion

JAMA Oncology2019-05-09519 citations

Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.

2018-01-1141 citations